RenovoRx Inc

RNXT

Company Profile

  • Business description

    RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

  • Contact

    2570 West El Camino Real
    Suite 320
    Mountain ViewCA94040
    USA

    T: +1 650 284-4433

    https://www.renovorx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    17

Stocks News & Analysis

stocks

Why don’t good returns guarantee a 5-star rating?

Amy Arnott explains how Morningstar’s stock ratings work.
stocks

Despite post earnings rally ASX share still cheap

Lifting our 2028 earnings estimate by 20%.
stocks

Overvalued ASX share has overly ambitious profit target

We think the new profit target is aggressive and unlikely to be met.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,958.0039.30-0.44%
CAC 408,216.78135.22-1.62%
DAX 4026,045.37553.27-2.08%
Dow JONES (US)50,759.42848.75-1.64%
FTSE 10010,689.87191.68-1.76%
HKSE23,289.02219.15-0.93%
NASDAQ24,328.38181.38-0.74%
Nikkei 22558,696.54163.89-0.28%
NZX 50 Index14,301.795.17-0.04%
S&P 5007,340.5376.06-1.03%
S&P/ASX 2008,844.9038.30-0.43%
SSE Composite Index3,576.518.06-0.22%

Market Movers